NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
Clinical Trials
27 trialsNCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT06192784 2024-01-09
CCGLC-012
Tongji Hospital
Phase 2 Unknown
NCT06129955 2023-11-13
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05823987 2023-06-27
OPTIONS-05
Fudan University
Phase 2 Unknown
NCT05893056 2023-06-27
CASTLE-09
Fudan University
Phase 2 Unknown
NCT05903456 2023-06-15
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04211168 2023-03-29
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04368078 2023-03-29
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05781074 2023-03-24
CASTLE-08
Fudan University
Phase 2 Unknown
NCT05312216 2023-01-26
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Phase 2 Unknown
NCT05410197 2022-10-12
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
Sun Yat-sen University
Phase 2 Unknown
NCT05509478 2022-09-10
LEADER-001
The First Hospital of Jilin University
Phase 2 Unknown
NCT05036798 2022-09-07
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT03732495 2022-03-29
LENVOS
Centre Leon Berard
Phase 2 Unknown
NCT05291052 2022-03-22
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04989322 2021-12-08
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
The University of Hong Kong
Phase 2 Unknown
NCT04490694 2021-09-24
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04814043 2021-09-22
PLATIC
Sun Yat-sen University
Phase 2 Unknown
NCT03951597 2021-07-07
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04042805 2021-03-02
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04170179 2021-02-23
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University
Phase 2 Unknown
NCT04741165 2021-02-05
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT04273100 2020-02-17
PLTHCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04241523 2020-01-27
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04227808 2020-01-14
Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown